Olink Investor Relations Material
Latest events
Q2 2023
Olink
Q1 2024
13 May, 2024
Q4 2023
25 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Olink Holding AB
Access all reports
Olink Holding AB develops and markets proteomics solutions for academic and pharmaceutical research. The company’s technology platform enables high-throughput protein biomarker discovery and validation. It serves customers in biomarker research, drug development, and diagnostics. The company is headquartered in Uppsala, Sweden, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
OLK
Country
🇺🇸 United States